Publications by authors named "M Crepy"

Background: The lack of attention to Chronic Hand Eczema (CHE) and the lack of a specific International Classification of Diseases code for CHE may have limited the assessment of CHE prevalence. To date, prevalence estimates have primarily been derived from (partly small) single-country studies.

Objectives: To estimate the annual prevalence of self-reported physician-diagnosed CHE across socio-demographic characteristics among adults in Canada, France, Germany, Italy, Spain, and the United Kingdom (UK).

View Article and Find Full Text PDF
Article Synopsis
  • Octylisothiazolinone (OIT) is a biocide used in leather products, raising concerns about allergic reactions, particularly in headphones.
  • A study reported cases of allergic contact dermatitis (ACD) in patients linked to headphones containing OIT, confirming its strong allergic potential through patch testing and chemical analysis.
  • The findings suggest that OIT is a significant sensitizer and highlight the need for safer use guidelines and improved product labeling in the leather industry to protect consumers.
View Article and Find Full Text PDF
Article Synopsis
  • Chronic hand eczema is a painful, inflammatory condition affecting the hands and wrists, impacting patients' quality of life and ability to work; the DELTA 1 and DELTA 2 trials aimed to evaluate the effectiveness and safety of delgocitinib cream against a placebo.* -
  • Both studies were randomized, double-blind, and involved adult participants with moderate to severe chronic hand eczema, comparing the effects of twice-daily applications of delgocitinib cream to a placebo for 16 weeks, focusing on achieving a clear or almost clear skin condition.* -
  • Results showed that significantly more patients treated with delgocitinib achieved treatment success compared to the placebo group, with notable differences observed in both trials
View Article and Find Full Text PDF

Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely compromises adequate diagnostics of contact allergy, leading to serious consequences for the affected patients.

View Article and Find Full Text PDF